In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Symphony Neuro licenses Guilford's GPI 1485

Executive Summary

Symphony Neuro Development, a financing and clinical development structure, has been set up by VC company Symphony Capital in order to license exclusive US rights to Guilford Pharmaceuticals' neuroimmunophilin ligand GPI 1485 for Parkinson's disease and post-prostatectomy erectile dysfunction (in Phase II for both indications) and HIV-related dementia and neuropathy (both preclinical).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies